Health care providers should consider advising the use of a daily HIV prevention pill – called, pre-exposure prophylaxis or PrEP – to patients at substantial risk for HIV, according to new clinical guidelines released today.
When used consistently, PrEP has been proven effective among all populations at risk, including gay and bisexual men, heterosexual adults and people who inject drugs.
The new guidelines offer healthcare professionals information and tools to:
- Identify patients who are eligible for PrEP
- Provide appropriate monitoring and support, including HIV testing to confirm patients are HIV-negative before beginning PrEP and at regular intervals while using PrEP
- Counsel patients to adhere to daily PrEP use and to use condoms and other proven risk reduction strategies
An accompanying providers’ supplement includes checklists and interview guides to help clinicians discuss PrEP with their patients.
For more information, see our press release or broadcast quality audio and video sound bites from Dr. Jonathan Mermin, Director of CDC’s National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention. Additional reporter resources are available on the NCHHSTP online newsroom.
No hay comentarios:
Publicar un comentario